# Open Orphan Appoints finnCap Ltd as its joint broker

- Link: https://www.directorstalkinterviews.com/open-orphan-appoints-finncap-ltd-as-its-joint-broker/412820210
- Published: 2020-05-11T07:11:20+01:00
- Author: Giles Arbor

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
the rapidly growing specialist CRO pharmaceutical services company which has a focus
on orphan drugs and is the world leader in the testing of vaccines and antivirals
using human challenge study models, announced today the appointment of finnCap Ltd
as its joint broker with immediate effect.

Open Orphan is a rapidly growing specialist CRO pharmaceutical services company 
which has a focus on orphan drugs and is a world leader in the provision of virology
and vaccine challenge study services and viral laboratory services. It has Europe’s
only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital
London. hVIVO supports product development for customers developing antivirals, 
vaccines and respiratory therapeutics, all particularly relevant and topical in 
the environment of heightened awareness of Covid-19 in 2020. The Company also has
a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1
HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early 
March, the company is rapidly advancing a Coronavirus challenge study model and 
expects to be very active with many companies in the development of a Covid-19 vaccine.
No other company in the world has such a portfolio, with only two competitors globally
having 1 challenge study model each.

The company comprises of two commercial specialist CRO services businesses (Venn
and hVIVO) and is developing an early stage orphan drug genomics data platform business.
This platform captures valuable genetic data from patient populations with specific
diseases with designated orphan drug status and incorporating AI tools. In June 
2019, ORPH acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-
over and in January 2020 it completed the merger with [hVIVO plc](https://www.directorstalkinterviews.com/company/hvivo-plc/hvo.l).
Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing
and controls), preclinical, Phase I & II clinical trials design and execution. The
merger with hVIVO created a European full pharma services company broadening the
Company’s customer base and with complementary specialist CRO services, widened 
the range of the Company’s service offerings.

Share on:
